Secondary identifiers
interventional
N/A
1 country
N/A
Study Start
Not reported
Date not reportedPrimary Completion
Not reported
Date not reportedStudy Completion
Not reported
Date not reportedTo optimize the dosing and schedule of belantamab mafodotin in combination with Vd in RRMM in order to achieve similar efficacy and ensure improved toxicity profile
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 12, 2023
Actual (reported)1. ORR, defined as the percentage of participants with a Partial Response (PR) or better (i.e., PR, Very Good Partial Response (VGPR), Complete Response (CR), stringent Complete Response (sCR) ) 2. Incidence rate of Grade ≥3 ocular adverse events according to the keratopathy visual acuity (KVA) scale
1. Minimal Residual Disease (MRD) negativity rate, defined as the percentage of participants who are MRD negative by next-generation flow (NGF). 2. Time to Response (TTR), defined as the time between the date of first dose of study treatment and the first documented evidence of response (PR or better) among participants who achieve confirmed PR or better 3.Duration of Response (DoR), defined as the time from first documented evidence of PR or better until progressive disease (PD) or death due to PD among participants who achieve confirmed PR or better o 4. Progression-Free Survival (PFS), defined as the time from the date of first dose of study treatment until the earliest date of documented disease progression or death due to any cause 5.Overall survival (OS), is defined as the time between the date of the first dose of study treatment and death. 6.Concentration of belantamab mafodotin 7.Ocular findings on ophthalmic exam a)Cumulative event rate of ocular AEs to Week 16 (KVA scale) b)Incidence rate of ocular AEs by grade (KVA scale) c)Exposure adjusted incidence rate of ocular AEs by grade (KVA scale) d)Median duration of dose delay due to ocular AEs e)Percentage of participants requiring dose reductions, dose delays, and study treatment discontinuation due to ocular AEs f)Cumulative incidence of ocular AEs by grade g)Duration of ocular AEs h)Percentage of time on study with ocular AEs i)Change in best corrected visual acuity (BCVA) 8.Correlation of KVA grades with vision related anamnestic tool (Appendix 4)
CZ national declaration; IMP IMP:1; role: Test. Product, formulation and active substances are separate source declarations.
CZ national declaration; named active substance (D.3.8) in IMP IMP:1 (belantamab mafodotin)
Clinical Trial Information
SPONSOR CONTACT
First Posted
February 12, 2023
Download the complete EU Clinical Trials Register record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), EU Clinical Trials Register / EudraCT. Country-specific registry documents are preserved with their source URLs and retrieval dates; conflicting national declarations are not combined.
The source bundle preserves the original country texts with attribution and retrieval details. Normalized values are available separately.
Source retrieved:
Source: EU Clinical Trials Register (EMA). Retrieved: .
Each row shows the declaration in that country’s registry record. Planned participant counts are estimates, not confirmed recruitment.
Loading country declarations…
CZ national declaration; IMP IMP:2; role: Test. Product, formulation and active substances are separate source declarations.
CZ national declaration; named active substance (D.3.8) in IMP IMP:2 (Dexamethasone)
CZ national declaration; IMP IMP:3; role: Test. Product, formulation and active substances are separate source declarations.
CZ national declaration; named active substance (D.3.8) in IMP IMP:3 (Bortezomib)
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Countries publishing national protocol documents. This does not establish the number of recruiting sites.